Brokers Offer Predictions for Catalyst Pharmaceuticals Inc’s Q4 2019 Earnings (CPRX)

Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) – Research analysts at Piper Jaffray Companies lowered their Q4 2019 earnings estimates for Catalyst Pharmaceuticals in a report released on Thursday, November 8th. Piper Jaffray Companies analyst J. Catanzaro now forecasts that the biopharmaceutical company will earn $0.01 per share for the quarter, down from their prior estimate of $0.02. Piper Jaffray Companies has a “Overweight” rating and a $5.00 price target on the stock. Piper Jaffray Companies also issued estimates for Catalyst Pharmaceuticals’ FY2020 earnings at $0.26 EPS, FY2021 earnings at $0.66 EPS and FY2022 earnings at $1.12 EPS.

Other equities analysts have also recently issued research reports about the company. HC Wainwright reiterated a “buy” rating and set a $6.00 price objective on shares of Catalyst Pharmaceuticals in a report on Thursday, August 9th. ValuEngine cut Catalyst Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Wednesday, August 8th. Oppenheimer set a $6.00 price objective on Catalyst Pharmaceuticals and gave the company a “buy” rating in a report on Thursday, August 9th. Cantor Fitzgerald set a $8.00 price objective on Catalyst Pharmaceuticals and gave the company a “buy” rating in a report on Wednesday, October 3rd. Finally, BidaskClub upgraded Catalyst Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Thursday, October 18th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and five have issued a buy rating to the company. The stock currently has a consensus rating of “Buy” and an average price target of $5.71.

Shares of CPRX opened at $2.88 on Friday. Catalyst Pharmaceuticals has a 1 year low of $2.18 and a 1 year high of $4.51.

Catalyst Pharmaceuticals (NASDAQ:CPRX) last issued its earnings results on Thursday, November 8th. The biopharmaceutical company reported ($0.08) earnings per share (EPS) for the quarter, hitting the Zacks’ consensus estimate of ($0.08).

Several large investors have recently added to or reduced their stakes in CPRX. Rhumbline Advisers raised its position in Catalyst Pharmaceuticals by 34.7% in the 2nd quarter. Rhumbline Advisers now owns 90,725 shares of the biopharmaceutical company’s stock valued at $283,000 after buying an additional 23,383 shares during the last quarter. GSA Capital Partners LLP raised its position in Catalyst Pharmaceuticals by 295.7% in the 2nd quarter. GSA Capital Partners LLP now owns 380,605 shares of the biopharmaceutical company’s stock valued at $1,187,000 after buying an additional 284,409 shares during the last quarter. Millennium Management LLC raised its position in Catalyst Pharmaceuticals by 16.5% in the 2nd quarter. Millennium Management LLC now owns 1,610,176 shares of the biopharmaceutical company’s stock valued at $5,024,000 after buying an additional 227,918 shares during the last quarter. Northern Trust Corp raised its position in Catalyst Pharmaceuticals by 22.5% in the 1st quarter. Northern Trust Corp now owns 1,009,947 shares of the biopharmaceutical company’s stock valued at $2,414,000 after buying an additional 185,639 shares during the last quarter. Finally, Schwab Charles Investment Management Inc. raised its position in Catalyst Pharmaceuticals by 12.7% in the 2nd quarter. Schwab Charles Investment Management Inc. now owns 208,404 shares of the biopharmaceutical company’s stock valued at $651,000 after buying an additional 23,500 shares during the last quarter. Institutional investors and hedge funds own 51.48% of the company’s stock.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases. Its product candidates include Firdapse, a proprietary form of amifampridine phosphate that has completed Phase III clinical trials for the treatment of patients with lambert-eaton myasthenic syndrome; is in Phase III clinical trial to treat congenital myasthenic syndromes; and is in Phase III clinical trial for the treatment of anti-MuSK antibody positive myasthenia gravis, as well as is in Phase II clinical trial for patients with spinal muscular atrophy type 3.

Read More: Why do companies issue stock splits?

Earnings History and Estimates for Catalyst Pharmaceuticals (NASDAQ:CPRX)

Receive News & Ratings for Catalyst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply